🔗 Permalink

Inventor profile of:

Braydon Charles GUILD

City:

Concord, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2025-05-22

Top Assignees for applications by Braydon Charles GUILD

The entities that hold a legal rights for patent applications filed by inventor GUILD Braydon Charles:

Translate Bio, Inc. 18 Lexington, MA United States
SHIRE HUMAN GENETIC THERAPIES, INC. 9 Lexington, MA United States
Translate Bio, Inc. 5 Cambridge, MA United States
NOVARTIS AG 4 Basel, Switzerland
Ethris GmbH 2 Planegg, Germany
RaNA Therapeutics, Inc. 2 Lexington, MA United States
ETHRIS GMBH 2 Martinsried, Germany
Translate Bio, Inc. 1 Waltham, MA United States
Shire Human Genetics Therapies, Inc. 1 Lexington, MA United States

Recent patent applications by GUILD Braydon Charles

Braydon Charles GUILD from Concord, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-05-22

US20250161221A1

Human necessities

Lyophilized Pharmaceutical Compositions Comprising A Lipid Nanoparticle

#2 | 2024-12-12

US20240408020A1

Human necessities

Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle

#3 | 2023-09-28

US20230302039A1

Human necessities

CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES

#4 | 2022-12-29

US20220411791A1

Chemistry; metallurgy

Nuclease Resistant Polynucleotides and Uses Thereof

#5 | 2022-06-30

US20220202718A1

Human necessities

Cleavable lipids

#6 | 2022-02-24

US20220054602A1

Human necessities

mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES

#7 | 2021-02-11

US20210038519A1

Human necessities

Lipid-derived neutral nanoparticles

#8 | 2020-07-30

US20200237671A1

Human necessities

Cleavable lipids

#9 | 2020-02-13

US20200046752A1

Human necessities

CFTR MRNA compositions and related methods and uses

#10 | 2019-10-17

US20190314284A1

Human necessities

Cleavable lipids

#11 | 2019-07-18

US20190216843A1

Human necessities

Synergistic enhancement of the delivery of nucleic acids via blended formulations

#12 | 2019-06-27

US20190192435A1

Human necessities

Lipid-derived neutral nanoparticles

#13 | 2019-06-20

US20190185410A1

Chemistry; metallurgy

Ionizable cationic lipids

#14 | 2019-04-04

US20190100753A1

Chemistry; metallurgy

Nuclease resistant polynucleotides and uses thereof

#15 | 2018-08-23

US20180236047A1

Human necessities

MRNA for use in treatment of human genetic diseases

#16 | 2018-06-21

US20180169020A1

Human necessities

Cleavable lipids

#17 | 2018-06-21

US20180169016A1

Human necessities

Lipid-derived neutral nanoparticles

#18 | 2018-06-21

US20180169015A1

Human necessities

Lipid-derived neutral nanoparticles

#19 | 2018-01-18

US20180015116A1

Human necessities

CFTR MRNA compositions and related methods and uses

#20 | 2018-01-11

US20180008543A1

Human necessities

Cleavable Lipids

#21 | 2017-09-14

US20170260260A1

Chemistry; metallurgy

Compositions and methods for antibodies targeting complement protein C5

#22 | 2017-08-24

US20170240501A1

Chemistry; metallurgy

Ionizable cationic lipids

#23 | 2017-08-24

US20170239371A1

Human necessities

Lipid nanoparticle compositions and methods for MRNA delivery

#24 | 2016-06-02

US20160151409A1

Human necessities

Synergistic enhancement of the delivery of nucleic acids via blended formulations

#25 | 2016-04-21

US20160106772A1

Human necessities

CFTR mRNA compositions and related methods and uses

#26 | 2016-04-14

US20160101160A1

Human necessities

mRNA for use in treatment of human genetic diseases

#27 | 2016-02-04

US20160031981A1

Chemistry; metallurgy

Methods and compositions for delivering mRNA coded antibodies

#28 | 2016-02-04

US20160031975A1

Chemistry; metallurgy

Compositions and Methods for Antibodies Targeting Complement Protein C5

#29 | 2015-12-24

US20150366997A1

Human necessities

COMPOSITIONS AND METHODS FOR mRNA DELIVERY

#30 | 2015-09-24

US20150267192A1

Chemistry; metallurgy

NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF

#31 | 2015-06-18

US20150166462A1

Chemistry; metallurgy

Ionizable cationic lipids

#32 | 2015-03-26

US20150086613A1

Human necessities

Lipid-derived neutral nanoparticles

#33 | 2015-02-05

US20150038556A1

Chemistry; metallurgy

CFTR mRNA compositions and related methods and uses

#34 | 2015-01-01

US20150004217A1

Human necessities

mRNA for use in treatment of human genetic diseases

#35 | 2014-10-02

US20140294940A1

Human necessities

MRNA THERAPY FOR UREA CYCLE DISORDERS

#36 | 2014-10-02

US20140294939A1

Human necessities

Pulmonary delivery of mRNA

#37 | 2014-10-02

US20140294938A1

Human necessities

MRNA therapy for Fabry disease

#38 | 2014-09-25

US20140288160A1

Human necessities

Cleavable lipids

#39 | 2014-07-24

US20140206753A1

Chemistry; metallurgy

LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY

#40 | 2013-08-01

US20130195967A1

Human necessities

Liver specific delivery of messenger RNA

#41 | 2013-03-14

US20130064836A1

Chemistry; metallurgy

Compositions and methods for antibodies targeting complement protein C5

#42 | 2013-01-24

US20130022615A1

Chemistry; metallurgy

Compositions and Methods for Antibodies Targeting Complement Protein C5

#43 | 2012-06-07

US20120142756A1

Human necessities

mRNA for use in treatment of human genetic diseases

#44 | 2011-10-06

US20110244026A1

Human necessities

DELIVERY OF MRNA FOR THE AUGMENTATION OF PROTEINS AND ENZYMES IN HUMAN GENETIC DISEASES

#45 | 2010-11-18

US20100291106A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C3B

#46 | 2010-02-11

US20100034809A1

Chemistry; metallurgy

Compositions and methods for antibodies targeting complement protein C5

#47 | 2009-07-09

US20090175875A1

Chemistry; metallurgy

Molecules and Methods for Modulating Complement Component

InventorID:

52430 ⎘